Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1246
Shown on this page
12
Current sort
Recently updated
Campus scope
Yale, New Haven, CT
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Yale, New Haven, CT. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 889–900 of 1,246 matching trials with a site at Yale, New Haven, CT.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 2 Interventional

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

NCT05642572
Status at this site: Recruiting
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Capmatinib, Computed Tomography, Magnetic Resonance Imaging, Osimertinib, Ramucirumab
Procedure · Drug · Biological
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
454
States / cities
Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 360 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 29, 2026, 6:37 PM EDT
Active, not recruiting No phase listed Observational

Tumor-induced Osteomalacia Disease Monitoring Program

NCT04783428
Site status not listed — check the official record
View directory record Official record
Conditions
Tumor-induced Osteomalacia (TIO)
Interventions
No intervention
Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
5
States / cities
New Haven, Connecticut • Bloomington, Indiana • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 29, 2026, 6:37 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women

NCT05547048
Status at this site: Recruiting
View directory record Official record
Conditions
HIV, Opioid Use Disorder, eHealth
Interventions
Decision Aid, Athena strategy
Behavioral · Combination Product
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 29, 2026, 6:37 PM EDT
Active, not recruiting Not applicable Interventional Results available

SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial

NCT04722250
Site status not listed — check the official record
View directory record Official record
Conditions
Symptomatic Aortic Stenosis, Aortic Valve Stenosis, Aortic Valve Replacement
Interventions
Medtronic Evolut PRO, Evolut PRO+ or Evolut FX (where commercially available) TAV Systems, Edwards SAPIEN 3 or SAPIEN 3 Ultra THV Systems
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
18 Years and older
Enrollment
1,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
61
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 29, 2026, 6:37 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

NCT05092347
Site status not listed — check the official record
View directory record Official record
Conditions
Chronic Kidney Disease (CKD)
Interventions
Vonsetamig
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 29, 2026, 6:37 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

NCT06950385
Status at this site: Recruiting
View directory record Official record
Conditions
Familial Adenomatous Polyposis (FAP)
Interventions
eRapa (encapsulated rapamycin), Placebo
Drug
Lead sponsor
Rapamycin Holdings Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
18
States / cities
Arcadia, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 29, 2026, 6:37 PM EDT
Recruiting Phase 1 Interventional

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

NCT06917079
Status at this site: Recruiting
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Non-Small Lung Cell Cancer, Metastatic Colorectal Cancer (CRC), KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12S, KRAS G12V, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Lung Carcinoma, Solid Tumor, Adult
Interventions
BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab, mFOLFOX6, BBO-10203, mFOLFIRINOX, Gemcitabine, Nab-paclitaxel
Drug
Lead sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Industry
Eligibility
18 Years and older
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
16
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 29, 2026, 6:37 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

NCT06917313
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Interventions
Fezolinetant, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 29, 2026, 6:37 PM EDT
Active, not recruiting Phase 1 Interventional

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

NCT06360354
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Interventions
Anvumetostat, Gemcitabine, Nab-paclitaxel, Modified FOLFIRINOX, RMC-6236
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
29
States / cities
Bakersfield, California • Duarte, California • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 29, 2026, 6:37 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Assessing the Effectiveness of Digital Wellness Modules on Perceived Quality of Life

NCT05810259
Status at this site: Recruiting
View directory record Official record
Conditions
Wellness, Quality of Life, Anxiety, Depression
Interventions
Caravan Wellness app
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 29, 2026, 6:37 PM EDT
Recruiting Phase 1Phase 2 Interventional

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

NCT03128996
Status at this site: Recruiting
View directory record Official record
Conditions
Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders, Immunologic Disorders, Hemoglobinopathies, Non-malignant Disorders
Interventions
RIC regimen, GVHD prophylaxis regimen
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Day to 21 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2033
U.S. locations
4
States / cities
New Haven, Connecticut • Wilmington, Delaware • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 29, 2026, 6:37 PM EDT
Active, not recruiting No phase listed Observational

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

NCT05988073
Site status not listed — check the official record
View directory record Official record
Conditions
Multifocal Motor Neuropathy
Interventions
Not listed
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 29, 2026, 6:37 PM EDT

About this Yale institution page

What this page lists
ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Yale University at any site, browse by condition, or browse by U.S. city.